Weed (BUDZ) Liabilities and Shareholders Equity (2010 - 2026)
Weed's (BUDZ) quarterly Liabilities and Shareholders Equity came in at $515713.0 in Q1 2026, down 10.33% year-on-year from $575128.0 in Q1 2025, and down 7.89% quarter-over-quarter from $559906.0 in Q4 2025.
Weed (BUDZ) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Weed's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $515713.0 for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 10.33% year-over-year to $515713.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 14.2% decrease from a year earlier, with the FY2025 full-year figure at $559906.0, down 24.17% from the prior year.
- Liabilities and Shareholders Equity declined to $515713.0 in Q1 2026 per BUDZ's latest filing, from $559906.0 in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.8 million in Q2 2022 and bottomed at $515713.0 in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $738366.0 (2024), against an average of $1.1 million.
- Across the five-year window, Liabilities and Shareholders Equity jumped 50.73% in 2022 and sank 53.89% in 2024, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $1.6 million in 2022, then sank by 44.67% to $904062.0 in 2023, then decreased by 18.33% to $738366.0 in 2024, then declined by 24.17% to $559906.0 in 2025, then slipped by 7.89% to $515713.0 in 2026.
- Per Business Quant, the three latest BUDZ Liabilities and Shareholders Equity figures stand at $515713.0 (Q1 2026), $559906.0 (Q4 2025), and $532267.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | 515,713.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515,713.00 |
| Dec 31, 2025 | 559,906.00 |
| Sep 30, 2025 | 532,267.00 |
| Jun 30, 2025 | 548,906.00 |
| Mar 31, 2025 | 575,128.00 |
| Dec 31, 2024 | 738,366.00 |
| Sep 30, 2024 | 596,818.00 |
| Jun 30, 2024 | 603,296.00 |
| Mar 31, 2024 | 703,807.00 |
| Dec 31, 2023 | 904,062.00 |
| Sep 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 1.63 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 1.81 Mn |
| Jun 30, 2021 | 1.84 Mn |